OBJECTIVES: To describe the full range of symptom exacerbations defined by people with interstitial cystitis/bladder pain syndrome and chronic prostatitis/chronic pelvic pain syndrome as 'flares', and to investigate their associated healthcare utilization and bother at two sites of the Multidisciplinary Approach to the Study of Chronic Pelvic Pain (MAPP) Epidemiology and Phenotyping study. SUBJECTS AND METHODS: Participants completed a flare survey that asked them: 1) whether they had ever had flares ('symptoms that are much worse than usual') that lasted <1 h, >1 h and <1 day, and >1 day; and 2) for each duration of flare, to report: their average length and frequency; their typical levels of urological and pelvic pain symptoms; and their levels of healthcare utilization and bother. We compared participants' responses to their non-flare MAPP values and by duration of flare using generalized linear mixed models. RESULTS: Of 85 participants, 76 (89.4%) completed the flare survey, 72 (94.7%) of whom reported experiencing flares. Flares varied widely in terms of their duration (seconds to months), frequency (several times per day to once per year or less), and intensity and type of symptoms (e.g. pelvic pain vs urological symptoms). Flares of all durations were associated with greater pelvic pain, urological symptoms, disruption to participants' activities and bother, with increasing severity of each of these factors as the duration of flares increased. Days-long flares were also associated with greater healthcare utilization. In addition to duration, symptoms (pelvic pain, in particular) were also significant determinants of flare-related bother. CONCLUSIONS: Our findings suggest that flares are common and associated with greater symptoms, healthcare utilization, disruption and bother. Our findings also show the characteristics of flares most bothersome to patients (i.e. increased pelvic pain and duration), and thus of greatest importance to consider in future research on flare prevention and treatment.
OBJECTIVES: To describe the full range of symptom exacerbations defined by people with interstitial cystitis/bladder pain syndrome and chronic prostatitis/chronic pelvic pain syndrome as 'flares', and to investigate their associated healthcare utilization and bother at two sites of the Multidisciplinary Approach to the Study of Chronic Pelvic Pain (MAPP) Epidemiology and Phenotyping study. SUBJECTS AND METHODS: Participants completed a flare survey that asked them: 1) whether they had ever had flares ('symptoms that are much worse than usual') that lasted <1 h, >1 h and <1 day, and >1 day; and 2) for each duration of flare, to report: their average length and frequency; their typical levels of urological and pelvic pain symptoms; and their levels of healthcare utilization and bother. We compared participants' responses to their non-flare MAPP values and by duration of flare using generalized linear mixed models. RESULTS: Of 85 participants, 76 (89.4%) completed the flare survey, 72 (94.7%) of whom reported experiencing flares. Flares varied widely in terms of their duration (seconds to months), frequency (several times per day to once per year or less), and intensity and type of symptoms (e.g. pelvic pain vs urological symptoms). Flares of all durations were associated with greater pelvic pain, urological symptoms, disruption to participants' activities and bother, with increasing severity of each of these factors as the duration of flares increased. Days-long flares were also associated with greater healthcare utilization. In addition to duration, symptoms (pelvic pain, in particular) were also significant determinants of flare-related bother. CONCLUSIONS: Our findings suggest that flares are common and associated with greater symptoms, healthcare utilization, disruption and bother. Our findings also show the characteristics of flares most bothersome to patients (i.e. increased pelvic pain and duration), and thus of greatest importance to consider in future research on flare prevention and treatment.
Authors: Kathleen Joy Propert; Mary McNaughton-Collins; Benjamin E Leiby; Michael P O'Leary; John W Kusek; Mark S Litwin Journal: J Urol Date: 2006-02 Impact factor: 7.450
Authors: Harris E Foster; Philip M Hanno; J Curtis Nickel; Christopher K Payne; Robert D Mayer; David A Burks; Claire C Yang; Toby C Chai; Karl J Kreder; Kenneth M Peters; Emily S Lukacz; Mary P FitzGerald; Liyi Cen; J Richard Landis; Kathleen J Propert; Wei Yang; John W Kusek; Leroy M Nyberg Journal: J Urol Date: 2010-03-29 Impact factor: 7.450
Authors: J Quentin Clemens; Elizabeth A Calhoun; Mark S Litwin; Mary McNaughton-Collins; John W Kusek; Evelyn M Crowley; J Richard Landis Journal: Urology Date: 2009-10-02 Impact factor: 2.649
Authors: Siobhan Sutcliffe; Graham A Colditz; Ratna Pakpahan; Catherine S Bradley; Melody S Goodman; Gerald L Andriole; H Henry Lai Journal: Neurourol Urodyn Date: 2013-11-23 Impact factor: 2.696
Authors: J Quentin Clemens; Chris Mullins; A Lenore Ackerman; Tamara Bavendam; Adrie van Bokhoven; Benjamin M Ellingson; Steven E Harte; Jason J Kutch; H Henry Lai; Katherine T Martucci; Robert Moldwin; Bruce D Naliboff; Michel A Pontari; Siobhan Sutcliffe; J Richard Landis Journal: Nat Rev Urol Date: 2019-03 Impact factor: 14.432
Authors: Siobhan Sutcliffe; Thomas Jemielita; H Henry Lai; Gerald L Andriole; Catherine S Bradley; J Quentin Clemens; Robert Gallop; Thomas M Hooton; Karl J Kreder; John N Krieger; John W Kusek; Jennifer Labus; M Scott Lucia; Sean Mackey; Bruce D Naliboff; Nancy A Robinson; Larissa V Rodriguez; Alisa Stephens-Shields; Adrie van Bokhoven; Kathleen Y Wolin; Yan Yan; Claire C Yang; J Richard Landis; Graham A Colditz Journal: J Urol Date: 2017-12-27 Impact factor: 7.450
Authors: Siobhan Sutcliffe; Catherine S Bradley; James Quentin Clemens; Aimee S James; Katy S Konkle; Karl J Kreder; Hing Hung Henry Lai; Sean C Mackey; Cody P Ashe-McNalley; Larissa V Rodriguez; Edward Barrell; Xiaoling Hou; Nancy A Robinson; Chris Mullins; Sandra H Berry Journal: Int Urogynecol J Date: 2015-03-20 Impact factor: 2.894
Authors: Siobhan Sutcliffe; Robert Gallop; Hing Hung Henry Lai; Gerald L Andriole; Catherine S Bradley; Gisela Chelimsky; Thomas Chelimsky; James Quentin Clemens; Graham A Colditz; Bradley Erickson; James W Griffith; Jayoung Kim; John N Krieger; Jennifer Labus; Bruce D Naliboff; Larissa V Rodriguez; Suzette E Sutherland; Bayley J Taple; John Richard Landis Journal: BJU Int Date: 2019-05-29 Impact factor: 5.588
Authors: J Curtis Nickel; Alisa Stephens; J Richard Landis; Chris Mullins; Adrie van Bokhoven; M Scott Lucia; Garth D Ehrlich Journal: J Urol Date: 2015-09-26 Impact factor: 7.450
Authors: H Henry Lai; Joel Vetter; Joseph Song; Gerald L Andriole; Graham A Colditz; Siobhan Sutcliffe Journal: Urology Date: 2019-01-22 Impact factor: 2.649
Authors: Tianlin Xu; H Henry Lai; Ratna Pakpahan; Joel Vetter; Gerald L Andriole; Catherine Bradley; Bruce D Naliboff; Graham A Colditz; Siobhan Sutcliffe Journal: Neurourol Urodyn Date: 2019-09-04 Impact factor: 2.367
Authors: Irum Javed; Tiange Yu; Jieni Li; Ratna Pakpahan; Melissa Milbrandt; Gerald L Andriole; Jerry L Lowder; H Henry Lai; Graham A Colditz; Siobhan Sutcliffe Journal: J Urol Date: 2020-12-21 Impact factor: 7.600
Authors: Dean A Tripp; Joel Dueck; Ronald R Holden; Julia Moreau; R Christopher Doiron; J Curtis Nickel Journal: Can Urol Assoc J Date: 2021-12 Impact factor: 1.862
Authors: Steven E Harte; Andrew Schrepf; Robert Gallop; Grant H Kruger; Hing Hung Henry Lai; Siobhan Sutcliffe; Megan Halvorson; Eric Ichesco; Bruce D Naliboff; Niloofar Afari; Richard E Harris; John T Farrar; Frank Tu; John Richard Landis; Daniel J Clauw Journal: Pain Date: 2019-06 Impact factor: 7.926